AbbVie, Others Move To End Generic Bystolic Antitrust Claims
By Khorri Atkinson · February 9, 2021, 10:42 PM EST
AbbVie Inc. and subsidiaries have fired back against a consolidated class action accusing the drug giant of reaping millions of dollars in profit by paying competitors to delay generic forms of...
To view the full article, register now.